Stem cell eye injection tested to halt blinding disease
NCT ID NCT02286089
Summary
This early-stage study is testing the safety of a new treatment for advanced dry age-related macular degeneration (AMD), a leading cause of vision loss. Doctors are injecting lab-grown retinal cells derived from human embryonic stem cells into the eyes of 24 patients with severe vision loss from the disease. The main goal is to see if the procedure is safe and if the transplanted cells can survive and potentially slow down the disease's progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Eye Institute
Cincinnati, Ohio, 45242, United States
-
Hadassah Medical Center
Jerusalem, 9112001, Israel
-
Kaplan Medical Center
Rehovot, 76100, Israel
-
Mid Atlantic Retina
Philadelphia, Pennsylvania, 19107, United States
-
Rabin Medical Center
Petah Tikva, 4941492, Israel
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906, Israel
-
West Coast Retina Medical Group
San Francisco, California, 94109, United States
Conditions
Explore the condition pages connected to this study.